| Year |
Citation |
Score |
| 2024 |
Hanamura T, Yokoyama K, Kitano S, Kagamu H, Yamashita M, Terao M, Okamura T, Kumaki N, Hozumi K, Iwamoto T, Honda C, Kurozumi S, Richer JK, Niikura N. Investigating the immunological function of alpha-2-glycoprotein 1, zinc-binding in regulating tumor response in the breast cancer microenvironment. Cancer Immunology, Immunotherapy : Cii. 73: 42. PMID 38349455 DOI: 10.1007/s00262-024-03629-1 |
0.322 |
|
| 2023 |
Welter L, Zheng S, Setayesh SM, Morikado M, Agrawal A, Nevarez R, Naghdloo A, Pore M, Higa N, Kolatkar A, Thiele JA, Sharma P, Moore HCF, Richer JK, Elias A, et al. Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics. Cancers. 15. PMID 37568766 DOI: 10.3390/cancers15153949 |
0.355 |
|
| 2023 |
Fernández NB, Sosa SM, Roberts JT, Recouvreux MS, Rocha-Viegas L, Christenson JL, Spoelstra NS, Couto FL, Raimondi AR, Richer JK, Rubinstein N. RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer. Cells. 12. PMID 36766786 DOI: 10.3390/cells12030444 |
0.472 |
|
| 2022 |
Porman AM, Roberts JT, Duncan ED, Chrupcala ML, Levine AA, Kennedy MA, Williams MM, Richer JK, Johnson AM. A single N6-methyladenosine site regulates lncRNA HOTAIR function in breast cancer cells. Plos Biology. 20: e3001885. PMID 36441764 DOI: 10.1371/journal.pbio.3001885 |
0.399 |
|
| 2022 |
Camp FA, Brunetti TM, Williams MM, Christenson JL, Sreekanth V, Costello JC, Hay ZLZ, Kedl RM, Richer JK, Slansky JE. Antigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8 T Cell Immunity. Cancers. 14. PMID 36139558 DOI: 10.3390/cancers14184397 |
0.336 |
|
| 2022 |
O'Neill KI, Kuo LW, Williams MM, Lind H, Crump LS, Hammond NG, Spoelstra NS, Caino MC, Richer JK. NPC1 Confers Metabolic Flexibility in Triple Negative Breast Cancer. Cancers. 14. PMID 35884604 DOI: 10.3390/cancers14143543 |
0.506 |
|
| 2022 |
Li Z, Spoelstra NS, Sikora MJ, Sams SB, Elias A, Richer JK, Lee AV, Oesterreich S. Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. Npj Breast Cancer. 8: 62. PMID 35538119 DOI: 10.1038/s41523-022-00426-w |
0.328 |
|
| 2022 |
Li Z, McGinn O, Wu Y, Bahreini A, Priedigkeit NM, Ding K, Onkar S, Lampenfeld C, Sartorius CA, Miller L, Rosenzweig M, Cohen O, Wagle N, Richer JK, Muller WJ, et al. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nature Communications. 13: 2011. PMID 35440136 DOI: 10.1038/s41467-022-29498-9 |
0.357 |
|
| 2022 |
Li Z, Wu Y, Yates ME, Tasdemir N, Bahreini A, Chen J, Levine KM, Priedigkeit NM, Nasrazadani A, Ali S, Buluwela L, Arnesen S, Gertz J, Richer JK, Troness B, et al. Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis. Cancer Research. PMID 35078818 DOI: 10.1158/0008-5472.CAN-21-2576 |
0.398 |
|
| 2021 |
Williams MM, Hafeez SA, Christenson JL, O'Neill KI, Hammond NG, Richer JK. Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways. Pharmaceuticals (Basel, Switzerland). 14. PMID 34832904 DOI: 10.3390/ph14111122 |
0.351 |
|
| 2021 |
Hanamura T, Christenson JL, O'Neill KI, Rosas E, Spoelstra NS, Williams MM, Richer JK. Secreted indicators of androgen receptor activity in breast cancer pre-clinical models. Breast Cancer Research : Bcr. 23: 102. PMID 34736512 DOI: 10.1186/s13058-021-01478-9 |
0.404 |
|
| 2021 |
Bergholtz H, Carter JM, Cesano A, Cheang MCU, Church SE, Divakar P, Fuhrman CA, Goel S, Gong J, Guerriero JL, Hoang ML, Hwang ES, Kuasne H, Lee J, Liang Y, ... ... Richer JK, et al. Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx Digital Spatial Profiler. Cancers. 13. PMID 34503266 DOI: 10.3390/cancers13174456 |
0.352 |
|
| 2021 |
Williams MM, Christenson JL, O'Neill KI, Hafeez SA, Ihle CL, Spoelstra NS, Slansky JE, Richer JK. MicroRNA-200c restoration reveals a cytokine profile to enhance M1 macrophage polarization in breast cancer. Npj Breast Cancer. 7: 64. PMID 34045467 DOI: 10.1038/s41523-021-00273-1 |
0.444 |
|
| 2021 |
Christenson JL, O'Neill KI, Williams MM, Spoelstra NS, Jones KL, Trahan GD, Reese J, Van Patten ET, Elias A, Eisner JR, Richer JK. Activity of combined androgen receptor antagonism and cell cycle inhibition in androgen receptor-positive triple-negative breast cancer. Molecular Cancer Therapeutics. PMID 33722849 DOI: 10.1158/1535-7163.MCT-20-0807 |
0.421 |
|
| 2020 |
Rosas E, Roberts JT, O'Neill K, Christenson JL, Williams MM, Hanamura T, Spoelstra NS, Vahrenkamp JM, Gertz J, Richer JK. A Positive Feedback Loop Between TGFβ and Androgen Receptor Supports Triple-Negative Breast Cancer Anoikis Resistance. Endocrinology. PMID 33294922 DOI: 10.1210/endocr/bqaa226 |
0.398 |
|
| 2020 |
Williams MM, Spoelstra NS, Arnesen S, O'Neill KI, Christenson JL, Reese J, Torkko KC, Goodspeed A, Rosas E, Hanamura T, Sams SB, Li Z, Oesterreich S, Riggins RB, Jacobsen BM, ... ... Richer JK, et al. Steroid hormone receptor and infiltrating immune cell status reveals therapeutic vulnerabilities of ESR1 mutant breast cancer. Cancer Research. PMID 33184106 DOI: 10.1158/0008-5472.CAN-20-1200 |
0.334 |
|
| 2020 |
Crump LS, Wyatt G, Rutherford TR, Richer JK, Porter WW, Lyons TR. Hormonal regulation of Semaphorin 7a in ER+ breast cancer drives therapeutic resistance. Cancer Research. PMID 33122307 DOI: 10.1158/0008-5472.CAN-20-1601 |
0.375 |
|
| 2020 |
Jordan K, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32928797 DOI: 10.1158/1078-0432.Ccr-20-1762 |
0.387 |
|
| 2020 |
Sawyer BT, Qamar L, Yamamoto TM, McMellen A, Watson ZL, Richer JK, Behbakht K, Schlaepfer IR, Bitler BG. Targeting fatty acid oxidation to promote anoikis and inhibit ovarian cancer progression. Molecular Cancer Research : McR. PMID 32198139 DOI: 10.1158/1541-7786.Mcr-19-1057 |
0.405 |
|
| 2020 |
Hanamura T, Christenson JL, O’Neill KI, Rosas E, Spoelstra NS, Williams MM, Richer JK. Abstract P6-05-06: Significance of prostate specific antigen as a predictor of androgen receptor activity in breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P6-05-06 |
0.407 |
|
| 2020 |
Richer JK, Williams MM, Spoelstra NS, Arnesen S, Christenson JL, O’Neill K, Reese JM, Blanchard ZD, Hanamura T, Jacobsen BM, Gertz J, Elias A. Abstract P6-04-13: Preclinical and clinical analyses of estrogen receptor alpha mutant metastatic breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-04-13 |
0.488 |
|
| 2020 |
Bitler BG, Sawyer B, Qamar L, Richer JK, Behbakht K, Schlaepfer IR. Abstract 5029: Targeting fatty acid oxidation to promote anoikis and inhibit ovarian cancer progression Tumor Biology. DOI: 10.1158/1538-7445.Am2020-5029 |
0.351 |
|
| 2019 |
Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Sawyer BT, Sullivan KD, Khanal S, Joshi M, Ferchaud-Roucher V, Smith H, Vanderlinden LA, Brubaker SW, Caino CM, Kim H, Espinosa JM, ... Richer JK, et al. Multi-Omic Approaches Identify Metabolic and Autophagy Regulators Important in Ovarian Cancer Dissemination. Iscience. 19: 474-491. PMID 31437751 DOI: 10.1016/J.Isci.2019.07.049 |
0.346 |
|
| 2019 |
MacFawn I, Wilson H, Selth LA, Leighton I, Serebriiskii I, Bleackley RC, Elzamzamy O, Farris J, Pifer PM, Richer J, Frisch SM. Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers. Molecular Immunology. 105: 137-149. PMID 30508726 DOI: 10.1016/J.Molimm.2018.11.006 |
0.389 |
|
| 2019 |
Reese J, Babbs B, Christenson J, Spoelstra N, Elias A, Eisner J, Baskin-Bey E, Gertz J, Richer J. Abstract P5-05-05: Targeting the androgen receptor with seviteronel, a CYP17 lyase and AR inhibitor, in triple negative breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P5-05-05 |
0.51 |
|
| 2019 |
Williams M, Christenson J, O'Neill K, Rogers T, Greene L, Slansky J, Richer J. Abstract P2-01-04: Epithelial-mesenchymal transition promotes triple negative breast cancer immune suppression Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P2-01-04 |
0.451 |
|
| 2018 |
Gordon MA, Babbs B, Cochrane DR, Bitler B, Richer JK. The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. Molecular Carcinogenesis. PMID 30294913 DOI: 10.1002/Mc.22919 |
0.417 |
|
| 2018 |
Rogers TJ, Christenson JL, Greene LI, O'Neill KI, Williams MM, Gordon MA, Nemkov T, D'Alessandro A, DeGala GD, Shin J, Tan AC, Cittelly DM, Lambert JR, Richer JK. Reversal of Triple-negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immune-Suppression. Molecular Cancer Research : McR. PMID 30213797 DOI: 10.1158/1541-7786.Mcr-18-0246 |
0.626 |
|
| 2018 |
Greene LI, Bruno TC, Christenson JL, D'Alessandro A, Culp-Hill R, Torkko K, Borges VF, Slansky JE, Richer JK. A Role for Tryptophan-2,3-dioxygenase in CD8 T Cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma. Molecular Cancer Research : McR. PMID 30143553 DOI: 10.1158/1541-7786.Mcr-18-0362 |
0.48 |
|
| 2018 |
Christenson JL, Trepel JB, Ali HY, Lee S, Eisner JR, Baskin-Bey ES, Elias AD, Richer JK. Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer. Hormones & Cancer. PMID 29340907 DOI: 10.1007/S12672-017-0314-5 |
0.468 |
|
| 2018 |
Smith LP, Harrell LM, Christenson JL, Bitler B, Slansky J, Richer JK. Abstract 5137: Tryptophan catabolism in ovarian cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2018-5137 |
0.365 |
|
| 2017 |
He L, Du Z, Xiong X, Ma H, Zhu Z, Gao H, Cao J, Li T, Li H, Yang K, Chen G, Richer JK, Gu H. Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer. Scientific Reports. 7: 14584. PMID 29109513 DOI: 10.1038/S41598-017-14607-2 |
0.45 |
|
| 2017 |
Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, Foright RM, Dooley G, Edgerton SM, Jindal S, Johnson GC, Richer JK, Kabos P, Thor AD, Schedin P, et al. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer. Hormones & Cancer. PMID 28741260 DOI: 10.1007/S12672-017-0302-9 |
0.442 |
|
| 2017 |
Barton VN, Christenson JL, Gordon MA, Greene LI, Rogers TJ, Butterfield K, Babbs B, Spoelstra NS, D'Amato NC, Elias A, Richer JK. Androgen receptor supports an anchorage-independent, cancer stem cell-like population in triple-negative breast cancer. Cancer Research. PMID 28512248 DOI: 10.1158/0008-5472.Can-16-3240 |
0.522 |
|
| 2017 |
Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle JD, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK. Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer. Molecular Cancer Therapeutics. PMID 28468774 DOI: 10.1158/1535-7163.Mct-17-0111 |
0.483 |
|
| 2017 |
Christenson JL, Butterfield KT, Spoelstra NS, Norris JD, Josan JS, Pollock JA, McDonnell DP, Katzenellenbogen BS, Katzenellenbogen JA, Richer JK. MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. Hormones & Cancer. PMID 28194662 DOI: 10.1007/S12672-017-0285-6 |
0.528 |
|
| 2017 |
Gordon MA, Cochrane DR, Betker J, Anchordoquy T, Richer JK. Abstract MIP-057: TARGETING THE LONG–NONCODING RNA MALAT1 IN OVARIAN CANCER Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Mip-057 |
0.465 |
|
| 2017 |
Gordon MA, D'Amato N, Christenson J, Babbs B, Gu H, Wulfkuhle J, Petricoin E, Elias A, Richer JK. Abstract 3610: Synergy between androgen receptor (AR)-targeting agents seviteronel (SEVI) or enzalutamide (ENZA) and mTOR or HER2 pathway-targeting agents in breast cancer Endocrinology. 77: 3610-3610. DOI: 10.1158/1538-7445.Am2017-3610 |
0.452 |
|
| 2016 |
Heinz RE, Rudolph MC, Ramanathan P, Spoelstra NS, Butterfield KT, Webb PG, Babbs BL, Gao H, Chen S, Gordon MA, Anderson SM, Neville MC, Gu H, Richer JK. Constitutive expression of microRNA-150 in mammary epithelium suppresses secretory activation and impairs de novo lipogenesis. Development (Cambridge, England). PMID 27729410 DOI: 10.1242/Dev.139642 |
0.463 |
|
| 2016 |
D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK. Cooperative Dynamics of AR and ER Activity in Breast Cancer. Molecular Cancer Research : McR. PMID 27565181 DOI: 10.1158/1541-7786.Mcr-16-0167 |
0.482 |
|
| 2016 |
Barton VN, Gordon MA, Richer JK, Elias A. Anti-androgen therapy in triple-negative breast cancer. Therapeutic Advances in Medical Oncology. 8: 305-8. PMID 27482289 DOI: 10.1177/1758834016646735 |
0.352 |
|
| 2016 |
Spoelstra NS, Cittelly DM, Christenson JL, Gordon MA, Elias A, Jedlicka P, Richer JK. Dicer Expression in Estrogen Receptor Positive versus Triple-Negative Breast Cancer: An Antibody Comparison. Human Pathology. PMID 27260947 DOI: 10.1016/J.Humpath.2016.05.014 |
0.5 |
|
| 2016 |
Greene LI, Bruno TC, Rogers TJ, Slansky JE, Borges VF, Richer JK. Abstract B55: Suppression of CD8 T-cell activation by tryptophan catabolism in triple-negative breast cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B55 |
0.481 |
|
| 2016 |
Elias A, Burris H, Patel, Schwartzberg L, Richer J, Kavalerchik E, Stopatschinskaja S, Gibbons J, Markova D, Steinberg J, Traina T. Abstract P1-16-05: MDV3100-08: A phase 1 study evaluating the safety and pharmacokinetics of enzalutamide plus fulvestrant in women with advanced hormone receptor-positive breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P1-16-05 |
0.406 |
|
| 2015 |
D'Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, Nemkov TG, D'Alessandro A, Hansen KC, Richer JK. A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer. Cancer Research. PMID 26363006 DOI: 10.1158/0008-5472.Can-15-2011 |
0.547 |
|
| 2015 |
Barton VN, D'Amato NC, Gordon MA, Christenson JL, Elias A, Richer JK. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Hormones & Cancer. PMID 26201402 DOI: 10.1007/S12672-015-0232-3 |
0.512 |
|
| 2015 |
Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, Richer JK. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Molecular Cancer Therapeutics. 14: 769-78. PMID 25713333 DOI: 10.1158/1535-7163.Mct-14-0926 |
0.497 |
|
| 2015 |
Niemeyer BF, Parrish JK, Spoelstra NS, Joyal T, Richer JK, Jedlicka P. Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes. Plos One. 10: e0116895. PMID 25603314 DOI: 10.1371/Journal.Pone.0116895 |
0.384 |
|
| 2015 |
Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 34: 3676-87. PMID 25241899 DOI: 10.1038/Onc.2014.298 |
0.613 |
|
| 2015 |
Gordon MA, D'Amato N, Gu H, Wong D, Elias A, Richer JK. Abstract P6-03-07: Targeting multiple pathways in breast cancer: Androgen receptor, HER2, and mTOR Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-03-07 |
0.502 |
|
| 2015 |
D'Amato NC, Jacobsen BM, Cochrane DR, Spoelstra NS, Babbs BL, Elias A, Richer JK. Abstract P3-04-06: Inhibiting androgen receptor nuclear localization decreases estrogen receptor (ER) activity and tumor growth in ER+ breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-04-06 |
0.535 |
|
| 2015 |
Barton VN, D'Amato NC, Gordon MA, Jacobsen BM, Richer JK. Abstract P3-04-02: Multiple subtypes of triple negative breast cancer are dependent on androgen receptor Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-04-02 |
0.534 |
|
| 2015 |
Thor AD, Fan Z, Wahdan-Alaswad R, Anderson SM, Richer JK, Edgerton SM. Abstract P1-08-02: Metformin blocks de novo synthesis of cholesterol in triple negative breast cancer cells Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P1-08-02 |
0.534 |
|
| 2015 |
Rogers T, D'Amato N, Nemkov T, Gordon M, Hansen K, Richer J. Abstract P1-07-12: Defining the role of the kynurenine pathway in mediating anoikis resistance in triple negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P1-07-12 |
0.514 |
|
| 2014 |
Wahdan-Alaswad RS, Cochrane DR, Spoelstra NS, Howe EN, Edgerton SM, Anderson SM, Thor AD, Richer JK. Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Hormones & Cancer. 5: 374-89. PMID 25213330 DOI: 10.1007/S12672-014-0188-8 |
0.807 |
|
| 2014 |
Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, et al. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Science Translational Medicine. 6: 229ra41. PMID 24670685 DOI: 10.1126/Scitranslmed.3008326 |
0.485 |
|
| 2014 |
Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, ... ... Richer JK, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Research : Bcr. 16: R7. PMID 24451109 DOI: 10.1186/Bcr3599 |
0.771 |
|
| 2013 |
Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng XS, Arnadottir SS, Richer JK, Anderson SM, Thor AD. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle (Georgetown, Tex.). 12: 3759-69. PMID 24107633 DOI: 10.4161/Cc.26641 |
0.432 |
|
| 2013 |
D'Amato NC, Howe EN, Richer JK. MicroRNA regulation of epithelial plasticity in cancer Cancer Letters. 341: 46-55. PMID 23228634 DOI: 10.1016/J.Canlet.2012.11.054 |
0.724 |
|
| 2013 |
Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA, Richer JK. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4 Oncogene. 32: 2555-2564. PMID 22751119 DOI: 10.1038/Onc.2012.275 |
0.805 |
|
| 2013 |
D'Amato NC, Cochrane DR, Barton VN, Bolin L, Edgerton SM, Bernales S, Gu H, Thor AD, Richer JK. Abstract IA18: Targeting the androgen receptor in multiple breast cancer subtypes Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-Ia18 |
0.535 |
|
| 2013 |
Barton V, D'Amato N, Richer J. Abstract A047: Targeting androgen receptor decreases proliferation of triple-negative breast cancer Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A047 |
0.558 |
|
| 2013 |
Cittelly DM, Cochrane DR, Howe EN, Dimitrova I, Post MD, Russell BR, Spillman MA, Richer JK. Abstract B70: Decreasing ovarian cancer metastases and progression via restoration of microRNAs that target mediators of anoikis- and chemoresistance. Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-B70 |
0.801 |
|
| 2013 |
D'Amato NC, Gu H, Cochrane DR, Bernales S, Jacobsen BM, Jedlicka P, Torkko KC, Edgerton SM, Thor AD, Elias AD, Protter AA, Richer JK. Abstract 4756: Elucidating the role of AR in breast cancer . Cancer Research. 73: 4756-4756. DOI: 10.1158/1538-7445.Am2013-4756 |
0.548 |
|
| 2012 |
Howe EN, Cochrane DR, Cittelly DM, Richer JK. miR-200c Targets a NF-κB Up-Regulated TrkB/NTF3 Autocrine Signaling Loop to Enhance Anoikis Sensitivity in Triple Negative Breast Cancer Plos One. 7. PMID 23185507 DOI: 10.1371/Journal.Pone.0049987 |
0.812 |
|
| 2012 |
Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Molecular Cancer Therapeutics. 11: 2556-65. PMID 23074172 DOI: 10.1158/1535-7163.Mct-12-0463 |
0.786 |
|
| 2012 |
Howe EN, Cochrane DR, Richer JK. The miR-200 and miR-221/222 microRNA families: Opposing effects on epithelial identity Journal of Mammary Gland Biology and Neoplasia. 17: 65-77. PMID 22350980 DOI: 10.1007/S10911-012-9244-6 |
0.805 |
|
| 2012 |
Cochrane DR, Jacobsen BM, Connaghan KD, Howe EN, Bain DL, Richer JK. Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer Molecular and Cellular Endocrinology. 355: 15-24. PMID 22330642 DOI: 10.1016/J.Mce.2011.12.020 |
0.781 |
|
| 2012 |
Cochrane DR, Spoelstra NS, Richer JK. The role of miRNAs in progesterone action. Molecular and Cellular Endocrinology. 357: 50-9. PMID 21952083 DOI: 10.1016/J.Mce.2011.09.022 |
0.415 |
|
| 2012 |
Elias AD, Richer JK, LoRusso P, Peterson AC, Steinberg JL, Mordenti J, Lopez C, Hudis C, Traina TA. MDV3100-08: A phase I open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of MDV3100 in women with incurable breast cancer. Journal of Clinical Oncology. 30: TPS668-TPS668. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps668 |
0.37 |
|
| 2012 |
Elias AD, Cochrane DR, Jacobsen BM, Cittelly DM, Howe EN, Jean A, Spoelstra NS, Protter AA, Richer JK. Effect of MDV3100, an androgen receptor signaling inhibitor, on tumor growth of estrogen and androgen receptor-positive (ER+/AR+) breast cancer xenografts. Journal of Clinical Oncology. 30: 564-564. DOI: 10.1200/Jco.2012.30.15_Suppl.564 |
0.78 |
|
| 2012 |
Cochrane DR, Jacobsen BM, Cittelly DM, Howe EN, Jean A, Spoelstra NS, Bernales S, Protter AA, Elias AD, Richer JK. Abstract LB-109: MDV3100, an androgen receptor signaling inhibitor, inhibits tumor growth in breast cancer preclinical models regardless of estrogen receptor status Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-109 |
0.779 |
|
| 2012 |
Philip MC, Lairet S, Clarke J, Richer J, El-Ashry D. Abstract 3171: Hyperactive MAPK dysregulation of microRNAs contributes to the ER-negative phenotype in breast cancer Cancer Research. 72: 3171-3171. DOI: 10.1158/1538-7445.Am2012-3171 |
0.601 |
|
| 2012 |
D'Amato N, Gu H, Lee M, Heinz R, Spoelstra N, Jean A, Richer J. Abstract P5-10-06: A functional role for miR-150 in breast cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P5-10-06 |
0.626 |
|
| 2012 |
Edgerton S, Richer J, Fan Z, Spoelstra N, Wahdan-Alsawad R, Arnadottir S, Thor A. Abstract P5-10-05: Novel Mechanisms of Metformin Action in TN Breast Cancer: Upregulation of miRNA 141 and 192, are Associated with a Decrease in TargetsGRB2andMSNInvolved in Signaling and Motility Respectively Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P5-10-05 |
0.612 |
|
| 2012 |
Wahdan-Alaswad R, Edgerton S, Terrell K, Spoelstra N, Thor A, Anderson S, Richer J. Abstract P5-10-04: Metformin mediated upregulation of microRNA-193 triggers apoptosis by decreasing fatty acid synthase Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P5-10-04 |
0.605 |
|
| 2012 |
Bernales S, Jacobsen B, D'Amato N, Guerrero J, Gómez F, Protter A, Elias A, Richer J. Abstract P2-14-02: Preclinical Evaluation of Enzalutamide in Breast Cancer Models Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P2-14-02 |
0.542 |
|
| 2011 |
Howe EN, Cochrane DR, Richer JK. Targets of miR-200c mediate suppression of cell motility and anoikis resistance Breast Cancer Research. 13. PMID 21501518 DOI: 10.1186/Bcr2867 |
0.784 |
|
| 2011 |
Cochrane DR, Cittelly DM, Richer JK. Steroid receptors and microRNAs: relationships revealed. Steroids. 76: 1-10. PMID 21093468 DOI: 10.1016/J.Steroids.2010.11.003 |
0.374 |
|
| 2011 |
Richer JK, Howe EN, Cochrane DR. Abstract 137: MicroRNA-200c restores anoikis sensitivity in breast and gynecological cancers Cancer Research. 71: 137-137. DOI: 10.1158/1538-7445.Am2011-137 |
0.794 |
|
| 2011 |
Richer J. MicroRNAs Regulate Endometrial and Ovarian Cancer Sensitivity to Anoikis and Chemotherapy. Biology of Reproduction. 85: 16-16. DOI: 10.1093/BIOLREPROD/85.S1.16 |
0.329 |
|
| 2010 |
Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D, Richer JK. MicroRNAs Link Estrogen Receptor Alpha Status and Dicer Levels in Breast Cancer Hormones and Cancer. 1: 306-319. PMID 21761362 DOI: 10.1007/S12672-010-0043-5 |
0.804 |
|
| 2010 |
Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, Jones FE. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Molecular Cancer. 9: 317. PMID 21172025 DOI: 10.1186/1476-4598-9-317 |
0.513 |
|
| 2010 |
Cittelly DM, Richer JK, Sartorius CA. Ovarian steroid hormones: what's hot in the stem cell pool? Breast Cancer Research : Bcr. 12: 309. PMID 20825628 DOI: 10.1186/Bcr2627 |
0.423 |
|
| 2010 |
Wright JA, Richer JK, Goodall GJ. microRNAs and EMT in mammary cells and breast cancer. Journal of Mammary Gland Biology and Neoplasia. 15: 213-23. PMID 20499142 DOI: 10.1007/S10911-010-9183-Z |
0.581 |
|
| 2010 |
Cochrane DR, Howe EN, Spoelstra NS, Richer JK. Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. Journal of Oncology. 2010: 821717. PMID 20049172 DOI: 10.1155/2010/821717 |
0.783 |
|
| 2010 |
Richer JK, Dimitrova I, Post M, Behbakht K. Abstract 2063: Reversal of chemoresistance to Paclitaxel by reintroduction of microRNA-200c in ovarian cancer cells Cancer Research. 70: 2063-2063. DOI: 10.1158/1538-7445.Am10-2063 |
0.596 |
|
| 2009 |
Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents Molecular Cancer Therapeutics. 8: 1055-1066. PMID 19435871 DOI: 10.1158/1535-7163.Mct-08-1046 |
0.79 |
|
| 2008 |
Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, Clark HR, Darling DS, Shroyer KR, Horwitz KB, Broaddus RR, Richer JK. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 21: 912-23. PMID 18487993 DOI: 10.1038/Modpathol.2008.82 |
0.75 |
|
| 2008 |
Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VF, Elias AD, Horwitz KB. Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Research and Treatment. 112: 489-501. PMID 18338247 DOI: 10.1007/S10549-008-9923-6 |
0.461 |
|
| 2008 |
Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Trapp S, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Research and Treatment. 112: 475-88. PMID 18327671 DOI: 10.1007/S10549-008-9897-4 |
0.466 |
|
| 2006 |
McLachlan-Burgess A, McCarthy S, Griffin C, Richer J, Cutler RG, Pandey S. Differential response induced by exposure to low-dose ionizing radiation in SHSY-5Y and normal human fibroblast cells. Applied Biochemistry and Biotechnology. 135: 159-78. PMID 17159239 DOI: 10.1385/Abab:135:2:159 |
0.344 |
|
| 2006 |
Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. British Journal of Cancer. 95: 1220-8. PMID 17043687 DOI: 10.1038/Sj.Bjc.6603354 |
0.403 |
|
| 2006 |
Balmer NN, Richer JK, Spoelstra NS, Torkko KC, Lyle PL, Singh M. Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: Correlation with clinicopathologic parameters and biomarkers. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 19: 1593-605. PMID 16980945 DOI: 10.1038/Modpathol.3800696 |
0.344 |
|
| 2006 |
Tung L, Abdel-Hafiz H, Shen T, Harvell DM, Nitao LK, Richer JK, Sartorius CA, Takimoto GS, Horwitz KB. Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. Molecular Endocrinology (Baltimore, Md.). 20: 2656-70. PMID 16762974 DOI: 10.1210/Me.2006-0105 |
0.338 |
|
| 2006 |
Spoelstra NS, Manning NG, Higashi Y, Darling D, Singh M, Shroyer KR, Broaddus RR, Horwitz KB, Richer JK. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Research. 66: 3893-902. PMID 16585218 DOI: 10.1158/0008-5472.Can-05-2881 |
0.442 |
|
| 2006 |
Harvell DM, Richer JK, Allred DC, Sartorius CA, Horwitz KB. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinology. 147: 700-13. PMID 16239301 DOI: 10.1210/En.2005-0617 |
0.42 |
|
| 2005 |
Carvajal A, Espinoza N, Kato S, Pinto M, Sadarangani A, Monso C, Aranda E, Villalon M, Richer JK, Horwitz KB, Brosens JJ, Owen GI. Progesterone pre-treatment potentiates EGF pathway signaling in the breast cancer cell line ZR-75. Breast Cancer Research and Treatment. 94: 171-83. PMID 16175315 DOI: 10.1007/S10549-005-7726-6 |
0.5 |
|
| 2005 |
Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR. Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 97: 328-41. PMID 16157482 DOI: 10.1016/J.Jsbmb.2005.06.032 |
0.448 |
|
| 2005 |
Jacobsen BM, Schittone SA, Richer JK, Horwitz KB. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Molecular Endocrinology (Baltimore, Md.). 19: 574-87. PMID 15563544 DOI: 10.1210/Me.2004-0287 |
0.493 |
|
| 2005 |
Kato S, Pinto M, Carvajal A, Espinoza N, Monso C, Sadarangani A, Villalon M, Brosens JJ, White JO, Richer JK, Horwitz KB, Owen GI. Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1. The Journal of Clinical Endocrinology and Metabolism. 90: 1181-8. PMID 15562024 DOI: 10.1210/Jc.2004-0857 |
0.504 |
|
| 2004 |
Wu J, Richer J, Horwitz KB, Hyder SM. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Cancer Research. 64: 2238-44. PMID 15026368 DOI: 10.1158/0008-5472.Can-03-3044 |
0.45 |
|
| 2003 |
Jacobsen BM, Richer JK, Sartorius CA, Horwitz KB. Expression profiling of human breast cancers and gene regulation by progesterone receptors. Journal of Mammary Gland Biology and Neoplasia. 8: 257-68. PMID 14973372 DOI: 10.1023/B:Jomg.0000010028.48159.84 |
0.527 |
|
| 2002 |
Jacobsen BM, Richer JK, Schittone SA, Horwitz KB. New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. The Journal of Biological Chemistry. 277: 27793-800. PMID 12021276 DOI: 10.1074/Jbc.M202584200 |
0.473 |
|
| 2002 |
Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. The Journal of Biological Chemistry. 277: 5209-18. PMID 11717311 DOI: 10.1074/Jbc.M110090200 |
0.503 |
|
| 2000 |
Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? The Journal of Steroid Biochemistry and Molecular Biology. 74: 255-9. PMID 11162933 DOI: 10.1016/S0960-0760(00)00101-1 |
0.472 |
|
| 2000 |
Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer. Steroids. 65: 579-84. PMID 11108862 DOI: 10.1016/S0039-128X(00)00116-1 |
0.46 |
|
| 1999 |
Lange CA, Richer JK, Horwitz KB. Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Molecular Endocrinology (Baltimore, Md.). 13: 829-36. PMID 10379882 DOI: 10.1210/Mend.13.6.0290 |
0.487 |
|
| 1999 |
Hodges YK, Richer JK, Horwitz KB, Horwitz LD. Variant estrogen and progesterone receptor messages in human vascular smooth muscle. Circulation. 99: 2688-93. PMID 10338464 DOI: 10.1161/01.Cir.99.20.2688 |
0.34 |
|
| 1998 |
Richer JK, Lange CA, Manning NG, Owen G, Powell R, Horwitz KB. Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. The Journal of Biological Chemistry. 273: 31317-26. PMID 9813040 DOI: 10.1074/Jbc.273.47.31317 |
0.444 |
|
| 1998 |
Lange CA, Richer JK, Shen T, Horwitz KB. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. The Journal of Biological Chemistry. 273: 31308-16. PMID 9813039 DOI: 10.1074/Jbc.273.47.31308 |
0.432 |
|
| 1998 |
Richer JK, Lange CA, Wierman AM, Brooks KM, Tung L, Takimoto GS, Horwitz KB. Progesterone receptor variants found in breast cells repress transcription by wild-type receptors. Breast Cancer Research and Treatment. 48: 231-41. PMID 9598870 DOI: 10.1023/A:1005941117247 |
0.494 |
|
| 1998 |
Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB. Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. The Journal of Biological Chemistry. 273: 10696-701. PMID 9553133 DOI: 10.1074/Jbc.273.17.10696 |
0.369 |
|
| 1997 |
Leslie KK, Kumar NS, Richer J, Owen G, Takimoto G, Horwitz KB, Lange C. Differential expression of the A and B isoforms of progesterone receptor in human endometrial cancer cells. Only progesterone receptor B is induced by estrogen and associated with strong transcriptional activation. Annals of the New York Academy of Sciences. 828: 17-26. PMID 9329820 DOI: 10.1111/J.1749-6632.1997.Tb48520.X |
0.404 |
|
| 1997 |
Miller MM, James RA, Richer JK, Gordon DF, Wood WM, Horwitz KB. Progesterone regulated expression of flavin-containing monooxygenase 5 by the B-isoform of progesterone receptors: implications for tamoxifen carcinogenicity. The Journal of Clinical Endocrinology and Metabolism. 82: 2956-61. PMID 9284726 DOI: 10.1210/jcem.82.9.4239 |
0.351 |
|
| 1997 |
Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Molecular Endocrinology (Baltimore, Md.). 11: 693-705. PMID 9171233 DOI: 10.1210/Mend.11.6.0004 |
0.349 |
|
| 1996 |
Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepressors. Molecular Endocrinology (Baltimore, Md.). 10: 1167-77. PMID 9121485 DOI: 10.1210/Mend.10.10.9121485 |
0.315 |
|
| Show low-probability matches. |